Movatterモバイル変換

[0]ホーム
URL:

PL379989A1 - Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same - Google Patents

Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same

Info

Publication number
PL379989A1
PL379989A1PL379989APL37998903APL379989A1PL 379989 A1PL379989 A1PL 379989A1PL 379989 APL379989 APL 379989APL 37998903 APL37998903 APL 37998903APL 379989 A1PL379989 A1PL 379989A1
Authority
PL
Poland
Prior art keywords
growth factor
nerve growth
opioid analgesic
administering
same
Prior art date
Application number
PL379989A
Other languages
Polish (pl)
Inventor
David L. Shelton
German J. Vergara
Original Assignee
Rinat Neuroscience Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=33415832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL379989(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rinat Neuroscience Corp.filedCriticalRinat Neuroscience Corp.
Publication of PL379989A1publicationCriticalpatent/PL379989A1/en

Links

Classifications

Landscapes

Abstract

The present invention features methods for treating or preventing pain comprising administering an amount of an antagonist antibody against the nerve growth factor and an amount of an opioid analgesic such that together they provide effective pain relief. The invention also features compositions comprising an antagonist antibody against the nerve growth factor antagonist and an opioid analgesic and kits containing the same.
PL379989A2002-10-082003-10-08Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the samePL379989A1 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US41734702P2002-10-082002-10-08
PCT/US2003/032113WO2004096122A2 (en)2002-10-082003-10-08Use of ngf antagonists and opioids for treating pain

Publications (1)

Publication NumberPublication Date
PL379989A1true PL379989A1 (en)2006-11-27

Family

ID=33415832

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PL379989APL379989A1 (en)2002-10-082003-10-08Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same

Country Status (18)

CountryLink
US (1)US20040131615A1 (en)
EP (2)EP2100902B1 (en)
JP (1)JP2006517524A (en)
KR (1)KR20050067174A (en)
CN (1)CN1878794B (en)
AT (1)ATE434625T1 (en)
AU (1)AU2003304060A1 (en)
BR (1)BR0315167A (en)
CA (1)CA2501694A1 (en)
DE (1)DE60328128D1 (en)
ES (2)ES2326881T3 (en)
MX (1)MXPA05003501A (en)
NO (1)NO20052221L (en)
PL (1)PL379989A1 (en)
RU (1)RU2005113996A (en)
UA (1)UA80447C2 (en)
WO (1)WO2004096122A2 (en)
ZA (1)ZA200502611B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN101653604A (en)*2001-05-302010-02-24基因技术股份有限公司Anti-ngf antibodies for the treatment of various disorders
AU2003284010A1 (en)*2002-10-042004-05-04Rinat Neuroscience Corp.Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
DK1556083T3 (en)2002-10-082011-04-04Rinat Neuroscience Corp Method of treating post-operative pain by administration of an antibody to nerve growth factor and composition containing the same
WO2005000194A2 (en)*2002-10-082005-01-06Rinat Neuroscience Corp.Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
KR101410692B1 (en)2002-12-242014-06-24리나트 뉴로사이언스 코프.Anti-ngf antibodies and methods using same
AU2011201157C1 (en)*2002-12-242017-09-07Rinat Neuroscience Corp.Anti-NGF antibodies and methods using same
US9498530B2 (en)2002-12-242016-11-22Rinat Neuroscience Corp.Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en)*2002-12-242009-08-04Pfizer Inc.Anti-NGF antibodies and methods using same
KR20050111598A (en)2003-02-192005-11-25리나트 뉴로사이언스 코퍼레이션Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
ITRM20030601A1 (en)*2003-12-242005-06-25Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
KR101637908B1 (en)2004-04-072016-07-11리나트 뉴로사이언스 코프.Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ITRM20050290A1 (en)2005-06-072006-12-08Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
ITRM20050332A1 (en)2005-06-242006-12-25Lay Line Genomics Spa USE OF MOLECULES ABLE TO BLOCK TRKA'S ACTIVITY TO STRENGTHEN THE EFFECTS OF ANALGESIC OPPIACEI ON PAIN.
WO2007035906A2 (en)2005-09-212007-03-29The Regents Of The University Of CaliforniaSystems and methods for imaging-treatment of pain
CA2790018C (en)*2006-12-212015-02-03Amgen Inc.Formulations
US8309088B2 (en)2007-08-102012-11-13Regeneron Pharmaceuticals, Inc.Method of treating osteoarthritis with an antibody to NGF
ME02239B (en)*2007-08-102015-04-30Regeneron PharmaHigh affinity human antibodies to human nerve growth factor
KR20130087632A (en)*2007-12-172013-08-06화이자 리미티드Treatment of interstitial cystitis
WO2009098238A1 (en)2008-02-042009-08-13Bioxell SpaAnti-trka antibodies and derivatives thereof
US20090286832A1 (en)*2008-05-152009-11-19Kiichiro NabetaNarcotic emulsion formulations for treatment of surgical pain
MX2011003144A (en)2008-09-242011-05-19Ribomic IncAptamer for ngf and use thereof.
NZ593937A (en)2008-12-082014-05-30Vm Pharma LlcCompositions of protein receptor tyrosine kinase inhibitors
EP2448970B1 (en)*2009-05-042014-07-09Abbott Research B.V.Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
AU2011230388B2 (en)2010-03-242016-09-08Fujimoto Pharmaceutical CorporationAptamer for NGF and use thereof
ES2910305T3 (en)2010-08-192022-05-12Zoetis Belgium S A Anti-NGF antibodies and their use
JP6105838B2 (en)*2010-08-242017-03-29国立大学法人 岡山大学 Pain treatment
US9539324B2 (en)2010-12-012017-01-10Alderbio Holdings, LlcMethods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en)2010-12-012015-06-30Alderbio Holdings LlcMethods of preventing or treating pain using anti-NGF antibodies
EP2646468B1 (en)2010-12-012018-07-25AlderBio Holdings LLCAnti-ngf compositions and use thereof
US11214610B2 (en)2010-12-012022-01-04H. Lundbeck A/SHigh-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en)2010-12-012015-07-14Alderbio Holdings LlcAnti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en)2010-12-012018-02-06Alderbio Holdings LlcAnti-NGF compositions and use thereof
CN108359008B (en)2011-05-202022-03-29H.伦德贝克公司Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments for the treatment or prevention of chronic and acute forms of diarrhea
EA201891284A1 (en)2011-05-202018-11-30Олдербайо Холдингз Ллк ANTIBODY COMPOSITIONS AGAINST CGRP AND THEIR APPLICATION
EA034747B1 (en)2011-05-202020-03-17Олдербайо Холдингз ЛлкMethod of preventing or inhibiting photophobia or light aversion using anti-cgrp antibodies
EP2731439A4 (en)2011-07-122014-12-03Merck Sharp & Dohme TrkA KINASE INHIBITORS, COMPOSITIONS CONTAINING SAME, AND ASSOCIATED METHODS
US20130295170A1 (en)*2012-05-032013-11-07Kydes Pharmaceuticals LlcCompositions for control of drug abuse
US9181261B2 (en)2012-05-222015-11-10Merck Sharp & Dohme Corp.TrkA kinase inhibitors, compositions and methods thereof
CN104364264B (en)2012-06-062018-07-24硕腾服务有限责任公司 Caninized anti-NGF antibodies and methods thereof
US8999992B2 (en)2013-03-152015-04-07Vm Pharma LlcCrystalline forms of tryosine kinase inhibitors and their salts
US20170114122A1 (en)2015-10-232017-04-27Alderbio Holdings LlcRegulation of glucose metabolism using anti-cgrp antibodies
WO2015039334A1 (en)2013-09-222015-03-26Merck Sharp & Dohme Corp.TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039333A1 (en)2013-09-222015-03-26Merck Sharp & Dohme Corp.TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
PL3102555T3 (en)2014-02-052021-12-20VM Oncology LLCCompositions of compounds and uses thereof
WO2015143654A1 (en)2014-03-262015-10-01Merck Sharp & Dohme Corp.TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en)2014-03-262015-10-01Merck Sharp & Dohme Corp.TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143652A1 (en)2014-03-262015-10-01Merck Sharp & Dohme Corp.TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
JP2017529356A (en)2014-09-172017-10-05ムンディファーマ インターナショナル コーポレイション リミテッド Crystal forms of tyrosine kinase inhibitors and salts thereof
WO2016161572A1 (en)2015-04-082016-10-13Merck Sharp & Dohme Corp.TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN105944084B (en)*2016-05-192024-05-03丽珠集团丽珠制药厂Nerve growth factor composition and preparation method thereof
MX2020009526A (en)2018-03-122020-10-28Zoetis Services LlcAnti-ngf antibodies and methods thereof.
JP2021525251A (en)*2018-05-212021-09-24イプセン バイオファーム リミテッドＩｐｓｅｎ Ｂｉｏｐｈａｒｍ Ｌｉｍｉｔｅｄ Suppression of bone cancer-induced allodynia
PE20211707A1 (en)2019-01-082021-09-01H Lundbeck As ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTICGRP ANTIBODIES
BR102020007149A8 (en)2020-04-062023-09-26H Lundbeck As Uses of an anti-cgrp or anti-cgrp-r antibody or a fragment thereof to improve the most bothersome symptom (mbs) and global impression of change (pgic) associated with migraine

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3773919A (en)1969-10-231973-11-20Du PontPolylactide-drug mixtures
SU975016A1 (en)*1979-12-171982-11-23Московский научно-исследовательский онкологический институт им.П.А.ГерценаAnalgetic composition
US4485045A (en)*1981-07-061984-11-27Research CorporationSynthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
US4544545A (en)1983-06-201985-10-01Trustees University Of MassachusettsLiposomes containing modified cholesterol for organ targeting
US5807715A (en)1984-08-271998-09-15The Board Of Trustees Of The Leland Stanford Junior UniversityMethods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en)*1984-12-181988-06-28Cetus CorporationPrecursor to nucleic acid probe
US4683202A (en)*1985-03-281987-07-28Cetus CorporationProcess for amplifying nucleic acid sequences
US4683195A (en)*1986-01-301987-07-28Cetus CorporationProcess for amplifying, detecting, and/or-cloning nucleic acid sequences
US4676980A (en)*1985-09-231987-06-30The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesTarget specific cross-linked heteroantibodies
US4777127A (en)*1985-09-301988-10-11Labsystems OyHuman retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en)1986-01-231986-02-26Wilson R HNucleotide sequences
US4800159A (en)*1986-02-071989-01-24Cetus CorporationProcess for amplifying, detecting, and/or cloning nucleic acid sequences
US6548640B1 (en)*1986-03-272003-04-15Btg International LimitedAltered antibodies
IL85035A0 (en)1987-01-081988-06-30Int Genetic EngPolynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en)1987-02-071987-03-11Al Sumidaie A M KObtaining retrovirus-containing fraction
US5219740A (en)*1987-02-131993-06-15Fred Hutchinson Cancer Research CenterRetroviral gene transfer into diploid fibroblasts for gene therapy
WO1989009225A1 (en)1988-03-281989-10-05The Regents Of The University Of CaliforniaNerve growth factor peptides
US5422120A (en)1988-05-301995-06-06Depotech CorporationHeterovesicular liposomes
AP129A (en)1988-06-031991-04-17Smithkline Biologicals S AExpression of retrovirus gag protein eukaryotic cells
US5047335A (en)*1988-12-211991-09-10The Regents Of The University Of Calif.Process for controlling intracellular glycosylation of proteins
US5530101A (en)1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
EP0832980B1 (en)1989-01-232002-06-19Chiron CorporationRecombinant therapies for infection and hyperproliferative disorders
US5703055A (en)1989-03-211997-12-30Wisconsin Alumni Research FoundationGeneration of antibodies through lipid mediated DNA delivery
US6673776B1 (en)1989-03-212004-01-06Vical IncorporatedExpression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
AU5344190A (en)1989-03-211990-10-22Vical, Inc.Expression of exogenous polynucleotide sequences in a vertebrate
EP0845537A1 (en)1989-08-181998-06-03Chiron CorporationRecombinant retroviruses delivering vector constructs to target cells
US5585362A (en)1989-08-221996-12-17The Regents Of The University Of MichiganAdenovirus vectors for gene therapy
US5656435A (en)*1989-08-281997-08-12Takeda Chemical Industries, Ltd.Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof
US5013556A (en)*1989-10-201991-05-07Liposome Technology, Inc.Liposomes with enhanced circulation time
ZA911974B (en)1990-03-211994-08-22Res Dev FoundationHeterovesicular liposomes
US5427908A (en)1990-05-011995-06-27Affymax Technologies N.V.Recombinant library screening methods
US5147294A (en)1990-10-011992-09-15Trustees Of Boston UniversityTherapeutic method for reducing chronic pain in a living subject
FR2669336B1 (en)*1990-11-201993-01-22Adir NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5278299A (en)*1991-03-181994-01-11Scripps Clinic And Research FoundationMethod and composition for synthesizing sialylated glycosyl compounds
DE69233482T2 (en)1991-05-172006-01-12Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en)1991-06-141994-03-03Genentech, Inc.Method for making humanized antibodies
GB9115364D0 (en)1991-07-161991-08-28Wellcome FoundAntibody
ES2197145T3 (en)1991-08-202004-01-01The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services TRANSFER OF GENES MEDIATED BY ADENOVIRUS TO GASTROINTESTINAL.
AU669124B2 (en)1991-09-181996-05-30Kyowa Hakko Kirin Co., Ltd.Process for producing humanized chimera antibody
DK0605522T3 (en)1991-09-232000-01-17Medical Res Council Process for producing humanized antibodies
ES2136092T3 (en)1991-09-231999-11-16Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
WO1993010218A1 (en)1991-11-141993-05-27The United States Government As Represented By The Secretary Of The Department Of Health And Human ServicesVectors including foreign genes and negative selective markers
GB9125623D0 (en)1991-12-021992-01-29Dynal AsCell modification
US5714350A (en)1992-03-091998-02-03Protein Design Labs, Inc.Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (en)1992-03-161993-09-17Centre Nat Rech ScientDefective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
US5733743A (en)1992-03-241998-03-31Cambridge Antibody Technology LimitedMethods for producing members of specific binding pairs
EP0650370A4 (en)1992-06-081995-11-22Univ California METHODS AND COMPOSITIONS FOR TARGETING SPECIFIC TISSUES.
US5342942A (en)*1992-06-091994-08-30Warner-Lambert CompanyPyrazoloquinazolone derivatives as neurotrophic agents
CA2137361A1 (en)1992-06-101993-12-23W. French AndersonVector particles resistant to inactivation by human serum
GB2269175A (en)1992-07-311994-02-02Imperial CollegeRetroviral vectors
US6210671B1 (en)1992-12-012001-04-03Protein Design Labs, Inc.Humanized antibodies reactive with L-selectin
JPH08503855A (en)1992-12-031996-04-30ジェンザイム・コーポレイション Gene therapy for cystic fibrosis
US5604260A (en)*1992-12-111997-02-18Merck Frosst Canada Inc.5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5981568A (en)1993-01-281999-11-09Neorx CorporationTherapeutic inhibitor of vascular smooth muscle cells
US5409944A (en)*1993-03-121995-04-25Merck Frosst Canada, Inc.Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
ATE227979T1 (en)1993-04-222002-12-15Skyepharma Inc MULTIVESICULAR LIPOSOMES WITH ENCAPSULATED CYCLODEXTRIN AND PHARMACOLOGICALLY ACTIVE COMPOUNDS AND METHOD FOR THE USE THEREOF
US6180377B1 (en)1993-06-162001-01-30Celltech Therapeutics LimitedHumanized antibodies
EP0705344B8 (en)1993-06-242006-05-10Advec Inc.Adenovirus vectors for gene therapy
ATE440957T1 (en)1993-09-152009-09-15Novartis Vaccines & Diagnostic RECOMBINANT ALPHAVIRUS VECTORS
US6015686A (en)1993-09-152000-01-18Chiron Viagene, Inc.Eukaryotic layered vector initiation systems
EP1637608B1 (en)1993-10-252009-07-22CANJI, Inc.Recombinant adenoviral vector and methods of use
RO116341B1 (en)1993-11-162001-01-30Depotech Corp La JoliaMultivesicle liposome and process for producing the same
CA2175893C (en)1993-11-232010-06-22Paul J. GodowskiProtein tyrosine kinases named rse
ATE163231T1 (en)1993-11-231998-02-15Genentech Inc KINASE RECEPTOR ACTIVATION TEST
GB9402331D0 (en)1994-02-071994-03-30Univ McgillNerve growth factor structural analogs and their uses
US5877016A (en)*1994-03-181999-03-02Genentech, Inc.Human trk receptors and neurotrophic factor inhibitors
US5844092A (en)1994-03-181998-12-01Genentech, Inc.Human TRK receptors and neurotrophic factor inhibitors
US6436908B1 (en)1995-05-302002-08-20Duke UniversityUse of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
CA2158977A1 (en)1994-05-091995-11-10James G. RespessRetroviral vectors having a reduced recombination rate
US6291247B1 (en)1994-05-112001-09-18Queen's University At KingstonMethods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
GB9514160D0 (en)*1994-07-251995-09-13Zeneca LtdAromatic compounds
AU4594996A (en)1994-11-301996-06-19Chiron Viagene, Inc.Recombinant alphavirus vectors
US6265150B1 (en)1995-06-072001-07-24Becton Dickinson & CompanyPhage antibodies
WO1997015593A1 (en)1995-10-251997-05-01Queen's University At KingstonNeurotrophin antagonists
GB9525180D0 (en)1995-12-081996-02-07Univ McgillDesign of hormone-like antibodies with agonistic and antagonistic fuctions
EP0953052B1 (en)1996-05-062009-03-04Oxford BioMedica (UK) LimitedCrossless retroviral vectors
UA67725C2 (en)1996-06-032004-07-15Cephalon IncK-252a derivatives and a method for improvement of functioning and cell survival enhancement
GB9616105D0 (en)1996-07-311996-09-11Univ KingstonTrkA binding site of NGF
NZ335291A (en)1996-10-212001-02-23Allelix BiopharmaNeurotrophin antagonist compositions
US6284794B1 (en)*1996-11-052001-09-04Head Explorer ApsMethod for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
DE19732928C2 (en)*1997-07-312000-05-18Gruenenthal Gmbh Use of substituted imidazolidine-2,4-dione compounds as pain relievers
AU9692198A (en)1997-10-101999-05-03Kevin J. DonahueGene delivery compositions and methods
GB9809951D0 (en)1998-05-081998-07-08Univ Cambridge TechBinding molecules
US6127401A (en)1998-06-052000-10-03Cephalon, Inc.Bridged indenopyrrolocarbazoles
US6652864B1 (en)1998-12-212003-11-25Asilomar Pharmaceuticals, Inc.Compounds for intracellular delivery of therapeutic moieties to nerve cells
CA2364484A1 (en)1999-03-092000-09-14University Of Southern CaliforniaMethod of promoting myocyte proliferation and myocardial tissue repair
US6492380B1 (en)*1999-05-172002-12-10Queen's University At KingstonMethod of inhibiting neurotrophin-receptor binding
US6468990B1 (en)1999-05-172002-10-22Queen's University At KingstonMethod of inhibiting binding of nerve growth factor to p75 NTR receptor
IT1306704B1 (en)1999-05-262001-10-02Sirs Societa Italiana Per La R MONOCLONAL ANTIBODIES AND ITS SYNTHETIC OR BIOTECHNOLOGICAL DERIVATIVES ENABLE TO ACT AS ANTAGONIST MOLECULES FOR NGF.
US6399780B1 (en)*1999-08-202002-06-04Cephalon, Inc.Isomeric fused pyrrolocarbazoles and isoindolones
US6849425B1 (en)1999-10-142005-02-01Ixsys, Inc.Methods of optimizing antibody variable region binding affinity
US6548062B2 (en)2000-02-292003-04-15Cephalon, Inc.Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (en)*2000-04-132001-10-19Warner Lambert CoUse of a nerve growth factor antagonist for the manufacture of a medicament for the prevention or treatment of chronic visceral pain
US7022484B2 (en)*2000-06-082006-04-04Board Of Regents, The University Of Texas SystemMethods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
GB0020504D0 (en)2000-08-182000-10-11Univ BristolTherapeutic method
US6630500B2 (en)2000-08-252003-10-07Cephalon, Inc.Selected fused pyrrolocarbazoles
AU2001288374A1 (en)2000-09-012002-03-22Glaxo Group LimitedSubstituted oxindole derivatives as tyrosine kinase inhibitors
CN101653604A (en)2001-05-302010-02-24基因技术股份有限公司Anti-ngf antibodies for the treatment of various disorders
US20030008807A1 (en)*2001-06-142003-01-09The Regents Of The University Of CaliforniaNovel signaling pathway for the production of inflammatory pain and neuropathy
US7288246B2 (en)*2001-09-132007-10-30The Board Of Regents Of The University Of OklahomaMethod of alleviating chronic pain via peripheral glutaminase regulation
US20040038874A1 (en)*2002-08-222004-02-26Osemwota OmoiguiMethod of treatment of persistent pain
US6919426B2 (en)*2002-09-192005-07-19Amgen Inc.Peptides and related molecules that modulate nerve growth factor activity
DK1556083T3 (en)*2002-10-082011-04-04Rinat Neuroscience Corp Method of treating post-operative pain by administration of an antibody to nerve growth factor and composition containing the same
KR101410692B1 (en)*2002-12-242014-06-24리나트 뉴로사이언스 코프.Anti-ngf antibodies and methods using same
KR20050111598A (en)*2003-02-192005-11-25리나트 뉴로사이언스 코퍼레이션Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
BRPI0412567B1 (en)*2003-07-152017-03-21Amgen Inc isolated antibody, or immunologically functional immunoglobulin fragment or antigen ligand thereof, pharmaceutical composition, nucleic acid molecule, medicament for treating a painful disorder or condition associated with increased ngf expression or increased ngf sensitivity, and, use of a pharmaceutically effective amount of antibody or immunologically functional immunoglobulin fragment or antigen binder thereof
KR101637908B1 (en)*2004-04-072016-07-11리나트 뉴로사이언스 코프.Methods for treating bone cancer pain by administering a nerve growth factor antagonist

Also Published As

Publication numberPublication date
US20040131615A1 (en)2004-07-08
DE60328128D1 (en)2009-08-06
UA80447C2 (en)2007-09-25
EP2100902B1 (en)2019-12-18
CN1878794A (en)2006-12-13
EP1575522A4 (en)2007-05-30
KR20050067174A (en)2005-06-30
RU2005113996A (en)2005-10-27
CN1878794B (en)2011-11-30
EP1575522B1 (en)2009-06-24
WO2004096122A2 (en)2004-11-11
JP2006517524A (en)2006-07-27
ES2767744T3 (en)2020-06-18
EP1575522A2 (en)2005-09-21
NO20052221D0 (en)2005-05-06
AU2003304060A1 (en)2004-11-23
CA2501694A1 (en)2004-11-11
ES2326881T3 (en)2009-10-21
ATE434625T1 (en)2009-07-15
WO2004096122A3 (en)2006-06-01
NO20052221L (en)2005-07-07
ZA200502611B (en)2006-06-28
MXPA05003501A (en)2005-10-19
EP2100902A1 (en)2009-09-16
BR0315167A (en)2005-08-23

Similar Documents

PublicationPublication DateTitle
EP1575522A4 (en)Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same
PL379983A1 (en)Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
MX9602818A (en)A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS.
WO2005000194A3 (en)Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
PL347469A1 (en)Use of certain drugs for treating nerve root injury
SI1556083T1 (en)Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same
MX2007005940A (en)Triazole compounds that modulate hsp90 activity.
WO2004038001A3 (en)Substituted tetracycline compounds for the treatment of malaria
WO2002039994A3 (en)Methods for the treatment and prevention of urinary stone disease
ATE332688T1 (en) USE OF CARBINOLES FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION
PL350568A1 (en)N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
GB0305153D0 (en)Identification of therapeutic compounds
MXPA03010407A (en)Prevention of addiction in pain management.
WO2003105891A3 (en)Use of hec1 antagonists in the treatment of proliferative disorders and cancer
BR0308911A (en) Compound, pharmaceutical composition, pain and migraine treatment methods, and use of a compound
AU2003282035A1 (en)Modulation of s6 kinase activity for the treatment of obestiy
AU2003239284A1 (en)Combination of pde-v inhibitors and nk1 antagonists for the treatment of depression
HK1080004A (en)Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same
AU8900498A (en)Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
BR0302183A (en) Compound, pharmaceutical composition and use of a compound

Legal Events

DateCodeTitleDescription
REFSDecisions on refusal to grant patents (taken after the publication of the particulars of the applications)
[8]ページ先頭
©2009-2025 Movatter.jp